News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
Chugai Pharma's Alecensa Trial Stopped Early After Successfully Meeting Primary Endpoint 2/10/2016
Transition Therapeutics (TTH.TO) Announces Second Quarter Fiscal 2016 Financial Results 2/10/2016
Alkermes (ALKS) Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia 2/10/2016
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Ascendis Pharma A/S To Present At The Leerink Partners Global Healthcare Conference 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
OSE Pharma Announces U.S. Initiation Of Atalante 1, The Company’s Global, Pivotal Phase III Trial For Tedopi Immunotherapy In Non-Small Cell Lung Cancer 2/4/2016
Steba Biotech Announces Positive Top-Line Results From Its Latin American Phase 3 Clinical Trial Of TOOKAD In Patients With Localized Prostate Cancer And Obtains First Marketing Authorization In Mexico 2/1/2016
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression 1/29/2016
Valeant (VRX) Announces FDA Acceptance Of BLA Submission For Brodalumab In Moderate-To-Severe Plaque Psoriasis 1/25/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
Steba Biotech Completes Its European Phase 3 Clinical Trial Of TOOKAD In Patients With Low-Risk Prostate Cancer And Submits Marketing Authorization Application To The European Medicines Agency 1/25/2016
Stock Craters as Alkermes (ALKS)' Depression Drug Fails in Two Late-Stage Trials 1/22/2016
Allergan (AGN) Release: VIBERZI (eluxadoline) Phase III Trial Results Published In The New England Journal of Medicine 1/21/2016
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer 1/20/2016
AEterna Zentaris (AEZS) Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase III Trial Of Macrilen 1/19/2016
Glioblastoma Treatment Market Will Expand to $3.3 Billion by 2024, GlobalData Report Says 1/14/2016
CrystalGenomics Partners With TR-Pharm For Acelex Commercialization In Turkey And MENA 1/12/2016
Cardiorentis Bags $60 Million and Adds Two Key Senior Execs to the Roster 1/11/2016
TiGenix Announces Acceptance Of Cx601 Abstract For Presentation At ECCO 2016 Congress 1/11/2016
Regeneron (REGN) And Sanofi (SNY) Announce Sarilumab Biologics License Application Accepted For Review By US FDA 1/8/2016
ViiV Healthcare To Progress Collaboration With Janssen To Develop The First Long-Acting, Two Drug Injectable Regimen For Treatment Of HIV-1 Infection 1/7/2016
Vtesse, Inc. Announces FDA's Granting Of Breakthrough Therapy Designation For VTS-270 In Niemann-Pick Type C1 Disease 1/6/2016
OSE Pharma Announces Initiation Of Its Pivotal Phase 3 trial Of Tedopi In Non-Small Cell Lung Cancer 1/6/2016
Acacia Pharma Announces Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In Prevention Of Post-Operative Nausea & Vomiting 1/5/2016
Pfizer (PFE)'s Pristiq Fails to Beat Placebo in Phase III MDD Study 12/23/2015
Kamada Ltd. (KMDA)'s Rabies Drug KamRab Meets Phase II/III Primary Endpoint 12/23/2015
BeyondSpring Pharmaceuticals Granted CTA By CFDA To Initiate China Arm Of Global Phase III Trial Of Lead Asset Plinabulin 12/22/2015
Merck KGaA (MKGAF.PK), Pfizer (PFE) Accelerate Immuno-Oncology Drug Avelumab into Phase III Ovarian and Bladder Cancer Trials 12/22/2015
Kitov (KTOV) Reports Additional Data From Its Phase III Trial On The Beneficial Blood Pressure Effects Of KIT-302 12/18/2015
Hutchison China MediTech (Chi-Med) Release: Initiation Of Sulfatinib Phase III Registration Study In Neuroendocrine Tumor Patients 12/18/2015
Celyad Announces The Publication Of Its CHART-1 Trial Design Methods Paper In The European Journal Of Heart Failure 12/16/2015
Braeburn Pharma And Camurus Announces Start Of Phase 3 Trial Of Long-Acting Buprenorphine Treatments For Opioid Dependence 12/15/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Two Phase III Studies Of Investigational Immunotherapy Avelumab In Advanced Gastric And Gastro-Esophageal Junction Cancers 12/9/2015
Hutchison China MediTech (Chi-Med) Release: Initiation Of Fruquintinib Phase III Registration Trial In Non-Small Cell Lung Cancer 12/8/2015
Boehringer Ingelheim Relesae: New Phase III Study Of Nintedanib In People With Systemic Sclerosis And Lung Fibrosis 12/8/2015
DBV Tech Announces Initiation Of Phase III Study Of Viaskin Peanut For The Treatment Of Peanut Allergic Children 12/8/2015
Amgen (AMGN) Submits Application In Europe To Expand Indication Of Kyprolis (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 12/7/2015
Atox Bio Enrolls First Patient In Phase III Study Of Potential Treatment For Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) 12/7/2015
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures 12/7/2015
TaiGen Biotechnology's Intravenous Taigexyn Successfully Achieved Primary Endpoint In Phase 3 Clinical Trial For Community Acquired Pneumonia 12/3/2015
Nuvo Research (NRI.TO) Provides Update on Pennsaid® 2% Phase 3 Clinical Trial 12/3/2015
Acacia Pharma: Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman 12/3/2015
OncoGenex (OGXI) Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses 12/2/2015
Janssen Biotech Inc. (JNJ) Submits Applications Seeking Approval Of STELARA In United States And European Union For Crohn's Disease 11/30/2015
AEterna Zentaris (AEZS) Affirms Fundamental Strength Of Business 11/30/2015
Otic Pharma Appoints Keith A. Katkin As Chairman Of The Board Of Directors 11/30/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Nine Months Ended September 30, 2015 11/30/2015
Regeneron (REGN) And Sanofi (SNY) Announce 18,000-Patient ODYSSEY OUTCOMES Trial Of Praluent Injection Fully Enrolled 11/24/2015
NovoCure Release: New Phase 3 Data Show Optune In Combination With Second Line Chemotherapy Is Superior To Second Line Chemotherapy Alone In Glioblastoma Patients At First Recurrence 11/23/2015
Amgen (AMGN) Release: European Commission Approves Kyprolis (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma 11/20/2015
AEterna Zentaris (AEZS) Announces First Patient Enrolled For Confirmatory Phase 3 Trial Of Macrilen For The Evaluation Of AGHD 11/19/2015
Teva (TEVA) Reports Positive Top-Line Results From Phase III Trials Evaluating Fluticasone Propionate/Salmeterol And Fluticasone Propionate Multidose Dry Powder Inhalers (Mdpis) In Patients With Asthma 11/19/2015
Morphotek Inc. Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunotherapy In Ovarian Cancer 11/17/2015
Vectura Group plc (VEC.L) Release: FLAME Study Shows Superiority Of Novartis AG (NVS)’ Ultibro Breezhaler Over Seretide In Reducing COPD Exacerbations 11/17/2015
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA 11/16/2015
Allergan (AGN) Presents EARLY Analysis Data At The American Academy of Ophthalmology Annual Meeting 11/13/2015
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) Announces Positive Results From Pivotal Clinical Trial Of Seciera (OTX-101) In Dry Eye Disease 11/13/2015
NeuroDerm (NDRM) Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease 11/11/2015
Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK)'s Lupus Drug Also Performs Well in Late Stage Study 11/11/2015
Albireo Announces The Initiation In Japan Of A Phase III Clinical Trial Of Elobixibat In Chronic Constipation By Ajinomoto 11/10/2015
Teva (TEVA) Snags Breakthrough Therapy Designation from the FDA for Huntington's Disease Drug 11/9/2015
Regeneron (REGN) And Sanofi (SNY) Present Results From Pivotal Phase 3 Study Of Sarilumab At American College of Rheumatology Annual Meeting 11/9/2015
Samsung Bioepis' SB4 And SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles In One-Year Phase 3 Clinical Studies 11/9/2015
Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates 11/9/2015
BiondVax Pharmaceuticals Announces Third Quarter 2015 Financial Results And Update 11/9/2015
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib U.S. Clinical Trials 11/6/2015
AEterna Zentaris (AEZS) Reports Third Quarter Financial And Operating Results 11/6/2015
OncoGenex (OGXI) To Present At The Stifel 2015 Healthcare Conference 11/6/2015
Nuvo Research (NRI.TO) Announces Successful Pennsaid2% Phase 3 Trial For Russia 11/5/2015
Axovant (AXON) To Present At Upcoming Investor Conferences 11/5/2015
Merck KGaA (MKGAF.PK) And Pfizer (PFE) Announce Initiation Of Phase III First-Line Trial Of Avelumab In Patients With Recurrent Or Stage IV Non-Small Cell Lung Cancer 11/4/2015
Sinovac Biotech Ltd. (SVA) To Participate In Morgan Stanley Asia Pacific Summit 11/4/2015
Positive Late-Stage Data Leads Alkermes (ALKS) to Believe it Can File an NDA for ALKS 8700 in 2018 10/29/2015
Shire (SHPG) CEO Believes Dry Eye Drug Will Boost Its Chances of Landing Baxalta (BXLT) 10/28/2015
Macrocure (MCUR) Stock Plunges 63% as Lead Drug Fails Phase III Study 10/28/2015
Transition Therapeutics (TTH.TO) Announces Presentation Of ELND005 Phase 2/3 Clinical Study Results At Clinical Trials In Alzheimer's Disease (CTAD) Conference 10/28/2015
GlaxoSmithKline (GSK)'s Heart Drug Losmapimod Flunks Phase III Trial 10/27/2015
GW Pharma (GWPH)'s Sativev Disappoints in Two Late-Stage Cancer Pain Trials 10/27/2015
Norgine Presents Phase III Study Design For NER1006, Its Low-Volume Bowel Cleansing Solution, At United European Gastroenterology Week 2015 10/27/2015
Resverlogix (RVX.TO) Commences Phase 3 Clinical Trial BETonMACE With Apabetalone 10/26/2015
Boehringer Ingelheim Release: New Analyses Showed Consistent Efficacy of OFEV (nintedanib) Across Various Patient Populations With Idiopathic Pulmonary Fibrosis (IPF) 10/26/2015
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On November 2-5, 2015 In Munich, Germany 10/26/2015
ImmunoGen (IMGN), Roche (RHHBY)'s Kadcyla Flunks Late-Stage Study 10/23/2015
Ipsen (IPN.PA) Presents Additional Results From A Phase III Clinical Trial Of The Investigational Use Of Dysport® In Children With Spastic Equinus Foot Deformity Due To Cerebral Palsy 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
Gilead (GILD)'s New HIV Drug Genvoya Shows Lower Side-Effects Over Longer Term in Two Late-Stage Studies 10/22/2015
Kitov Pharma Announces Completion Of Patient Recruitment For The Phase III Clinical Trial For KIT-302 10/21/2015
Janssen Research & Development Release:Phase 3 Data Show STELARA Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn's Disease 10/19/2015
Medifocus Announces Exclusive Agreement With Major Academic Medical Center To License Technology To Develop Heat-Activated And Tumor-Targeted Immunotherapy And Gene Therapy 10/16/2015
Motif Bio plc: Contract Signed With Leading CRO to Conduct Iclaprim Phase III Clinical Trials 10/16/2015
Allergan (AGN), Presents Data At The 2015 American Society Of Dermatologic Surgery (ASDS) Annual Meeting In Chicago 10/15/2015
Kuros Biosurgery AG To Present Positive kur-115 Pre Clinical Data For Interbody Spinal Fusion Treatment At The 2015 North American Spine Society 10/15/2015
RedHill Biopharma Provides Update On BEKINDA Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D 10/14/2015
AEterna Zentaris (AEZS): Data And Safety Monitoring Board Recommends Continuation Of ZoptEC Phase 3 Trial In Advanced Endometrial Cancer 10/13/2015
Can-Fite BioPharma (CFBI) Announces $4.8 Million Registered Direct Offering 10/13/2015
European Medicines Agency Grants Orphan Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 10/12/2015
30-Year-Old Hedge-Fund Whiz Kid’s Axovant (AXON) Starts Alzheimer’s Phase III Trial 10/7/2015
Onxeo Announces Positive DSMB Recommendation For Continuation Of Livatag Relive Study In HCC 10/5/2015
BiondVax Pharmaceuticals Establishes Capability For The Manufacture Of Clinical Grade Universal Flu Vaccine For Phase III Clinical Trials 10/1/2015
Can-Fite BioPharma (CFBI) To Present CF101 Psoriasis Data At Late Breaking Session Of The EADV Congress In Copenhagen On October 10, 2015 9/29/2015
OncoGenex (OGXI) Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes 9/28/2015
Amgen (AMGN) Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe 9/28/2015
Boehringer Ingelheim Release: COPD: New Data Support Role Of Spiolto Respimat As 1st-Line Maintenance Therapy And Show Superiority Over LABA/ICS 9/28/2015
Teva (TEVA) Presents New Reslizumab Data At European Respiratory Society (ERS) International Congress 2015 9/28/2015
Boehringer Ingelheim Release: ECC 2015: GIOTRIF (Afatinib) Demonstrates Superior Survival Compared To Tarceva (Erlotinib) For Patients With Previously Treated Advanced Squamous Cell Carcinoma Of The Lung, Independent Of EGFR Mutation Status 9/28/2015
Boehringer Ingelheim Release: VARGATEF Plus Docetaxel Significantly Reduced Tumour Burden In Lung Cancer Patients With Advanced Adenocarcinoma Compared To Docetaxel Alone 9/28/2015
FDA Grants Fast Track Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 9/17/2015
Lipid Therapeutics Licenses Rights To Its Novel Therapy For Ulcerative Colitis To Nestlé Health Science 9/16/2015
Allergan (AGN) Anti-Infective Portfolio Highlighted In 24 Abstracts At ICAAC 2015 9/16/2015
Analysts Bet Novo Nordisk A/S (NVO)'s Insulin Drug Will Get FDA Approval 9/15/2015
Sanofi (SNY) Plans LixiLan Filings After Meeting Phase III Primary Endpoint 9/15/2015
Avillion Announces Completion Of Enrolment In Phase III BFORE Trial To Assess BOSULIF (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 9/15/2015
Health Canada Approves Amgen (AMGN)'s New Cholesterol-Lowering Medication Repatha (evolocumab) 9/15/2015
Dr. Reddy's Laboratories Ltd. (RDY) Snags Exclusive Rights to Head Lice Product From Hatchtech 9/14/2015
BioBlast Pharma (ORPN) Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 9/14/2015
Innocoll (INNL) CMO Jumps to Pozen (POZN) as Pozen Moves to Ireland 9/14/2015
Theravance Biopharma (TBPH) And Mylan (MYL) Initiate Phase 3 Program For Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 9/14/2015
TRANSGENE (ENX:TNG) Reports Financial Results For First Six Months Of 2015 9/11/2015
Helsinn Group Release: Additional Data For anamorelin In ROMANA 1 And ROMANA 2 Studies Presented At 2015 International Association For The Study Of Lung Cancer (IASLC) World Conference On Lung Cancer (WCLC), In Denver 9/9/2015
FDA Grants Priority Review To Takeda (TKPYY)’s Ixazomib For Patients With Relapsed/Refractory Multiple Myeloma 9/9/2015
Neurimmune Therapeutics Receives Major Development Milestone Upon Initiation Of Global Phase 3 Studies With Aducanumab For Early Alzheimer's Disease 9/8/2015
RedHill Biopharma Ltd. (RDHL) Announces Standard-Of-Care Eradication Data From The RHB-105 Phase III Study Further Supporting The Study's Positive Results 9/8/2015
Hutchison China MediTech (Chi-Med) Release: Second Proof-Of-Concept Trial Of Fruquintinib Achieves Its Primary Endpoint 9/4/2015
Ascendis Pharma A/S To Present At Three Upcoming Investor Conferences 9/4/2015
Helsinn Group Signs Exclusive Agreement With Munipharma For The Distribution And Licence Of Anamorelin In Switzerland And Liechtenstein 9/3/2015
Axovant (AXON) To Present At Upcoming Investor Conferences 9/3/2015
Motif Bio plc, Release: FDA Grants Fast Track Designation For Iclaprim 9/3/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Xaracoll MATRIX-1 Phase III Study For The Treatment Of Postoperative Pain 9/2/2015
Bayer (BAY) Moves to Phase III Studies After Finerenone Cuts Deaths in Mid-Stage Trial 9/1/2015
Janssen Pharmaceuticals, Inc. Release: New Global Real-World Data From Atrial Fibrillation Studies Confirm The Safety Profile Of XARELTO 9/1/2015
Chiasma Reports Second Quarter 2015 Financial Results And Recent Business Highlights 9/1/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
Eisai Company (ESALY.PK) And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant 8/31/2015
Telesta Receives FDA BLA Filing Notification Letter And Priority Review Designation For MCNA(1) 8/31/2015
NeuroVive Discontinues Ciclomulsion for Myocardial Infarction 8/31/2015
Resverlogix (RVX.TO) Presents New Data At The European Society of Cardiology Congress 2015 On RVX-208 'Apabetalone' A Selective BET Inhibitor 8/31/2015
Ipsen (IPN.PA) Announces Publication In The Lancet Neurology Of The Results Of The Phase III Randomized Study (NCT01313299) Showing Efficacy And Safety Of Dysport (Abobotulinumtoxina) In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
PRANA Biotechnology (PRAN) Reports FY15 Financial Results 8/27/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients 8/25/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
VBL Therapeutics (VBLX) Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma 8/20/2015
Macrocure (MCUR) Sinks as CureXcell Flunks Phase III Study 8/20/2015
LEO Pharma Release: New Study Investigating The Effect Of Low-Molecular-Weight Heparins On The Treatment Of Blood Clots In Cancer Patients 8/19/2015
Boehringer Ingelheim Release: CHMP Recommends Label Update For Giotrif With Addition Of Data Demonstrating Overall Survival Benefit For Patients With EGFR Mutation-Positive Lung Cancer 8/19/2015
Swedish Orphan Biovitrum Release: Results From B-YOND Study Reinforce Long-Term Clinical Profile Of Alprolix For The Treatment Of Haemophilia B 8/18/2015
Mesoblast (MSB.AX) Reports 2015 Financial Year Results And Provides Update On Phase III Chronic Heart Failure Program 8/17/2015
Chiasma Announces FDA Acceptance For Filing Of New Drug Application For Octreotide Capsules In Acromegaly 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
AEterna Zentaris (AEZS) Second Quarter Financial And Operating Results 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
CrystalGenomics Partners With Dong-A ST For Acelex Commercialization In Korea 8/13/2015
RedHill Biopharma Ltd. (RDHL) To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease 8/12/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
Horizon Pharma (HZNP) Announces Record Second Quarter 2015 Financial Results 8/10/2015
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015
TiGenix Obtains FDA's Endorsement Through Special Protocol Assessment For Its Cx601 Phase III Registration Trial In The US 8/7/2015
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015
Orexigen (OREX) Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical 8/6/2015
Trimel Pharmaceuticals (TRL.TO) Announces Second Quarter 2015 Financial Results And Highlights 8/5/2015
Shionogi, Inc.'s Naldemedine Meets Endpoints In Phase III Study 8/3/2015
Ipsen (IPN.PA)’s Partner, Lexicon Pharma (LXRX), Announces Positive Results From TELESTAR Phase 3 Study Showing That Telotristat Etiprate Is Effective In The Treatment Of Carcinoid Syndrome Caused By Neuroendocrine Tumors Not Adequately Controlled By Somatostatin 8/3/2015
Cipher Pharma (DND.TO) Announces Successful Completion Of Second Phase III For Ozenoxacin 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Sanofi (SNY)'s Lixilan Hits Phase III Goal 7/29/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
As Biogen (BIIB), Eli Lilly (LLY) Fall Short, Roche (RHHBY) Intensifies Work on Two Alzheimer's Drugs 7/23/2015
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015
AstraZeneca PLC (AZN)'s Selumetinib Flunks Phase III Eye Cancer Study 7/22/2015
Onxeo: Update On ReLive, Livatag International Phase III Clinical Trial In HCC 7/21/2015
BioTie Therapies Corp. Announces Start Of Tozadenant Phase 3 Study In Parkinson's Disease 7/21/2015
Telesta Therapeutics Announces South Korean Partnership For MCNA & Concurrent Private Placement 7/20/2015
Pierre Fabre Release: Bladder Cancer Patients And Doctors Disappointed By Scottish Medicines Consortium's Negative Decision On Javlor (Vinflunine As Ditartrate) For The Treatment Of Adult Patients 7/13/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
Regeneron (REGN), Sanofi (SAN.PA)'s Praluent Delivers in Late Stage Trial 7/9/2015
AstraZeneca PLC (AZN) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China 7/8/2015
RedHill Biopharma Ltd. (RDHL) Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104 7/6/2015
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015
AEterna Zentaris (AEZS) Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer 6/30/2015
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015
CSL Behring Presents rIX-FP For Hemophilia B Phase III Data Evaluating Efficacy, Safety And Improved Dosing At ISTH 2015 6/25/2015
AEterna Zentaris (AEZS) Announces Selection Of ErgoMed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen In AGHD 6/25/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy 6/25/2015
Novo Nordisk A/S (NVO) Release: In A Phase 3 Trial, Novoeight(Antihemophilic Factor [Recombinant]) Provided Long-Term Efficacy And Safety In The Prophylaxis And Treatment Of Bleeds In People With Hemophilia A 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Nuvo Research Inc. (NRI.TO) Provides Update On International Licensing Of Pennsaid 2% 6/24/2015
Resverlogix (RVX.TO) Officially Attains Phase 3 Status With A European Regulatory Authority 6/22/2015
Boehringer Ingelheim Phase III Pradax Anticoagulant Antidote Study Meets Primary Endpoints 6/22/2015



//-->